ARS Pharmaceuticals Inc. (SPRY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ARS Pharmaceuticals Inc. (SPRY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.36

0.10 (0.89%)

At close: Jan 14, 2025, 3:59 PM

11.30

-0.53%

After-hours Jan 14, 2025, 05:07 PM EST

undefined% (undefined)

Bid	11.15
Market Cap	1.10B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.5
PE Ratio (ttm)	-22.72
Forward PE	n/a
Analyst	Buy

Ask	12.25
Volume	728,423
Avg. Volume (20D)	1,230,190
Open	11.91
Previous Close	11.26
Day's Range	11.03 - 11.98
52-Week Range	5.75 - 18.51
Beta	undefined

About SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 4, 2020

Employees 24

Stock Exchange NASDAQ

Ticker Symbol SPRY

Website https://ars-pharma.com

Analyst Forecast

According to 4 analyst ratings, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 146.48% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ARS Pharmaceuticals Inc. is scheduled to release its earnings on Mar 20, 2025, during market hours.
Analysts project revenue of $17.08M, reflecting a n/a YoY growth and earnings per share of -0.11, making a 57.14% increase YoY.

Why Price Moved

2 months ago · Source

-15.23%

ARS Pharmaceuticals shares are trading lower after... Unlock content with Pro Subscription

2 months ago · Source

+2.64%

ARS Pharmaceuticals shares are trading higher after the company announced an exclusive rights licensing with its neffy allergic reaction treatment and ALK-Abello.

News

1 day ago · investors.com

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.

2 months ago · seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Straus - Investor Relations Richard Lowenthal - Co-Founder, President a...

2 months ago · zacks.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.

2 months ago · benzinga.com

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.

2 months ago · zacks.com

Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 67.6% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questi...

2 months ago · zacks.com

Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY)

ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that ma...